神经分泌生物科学上调Ingrezza(Valbenazine) 2026年净销售额指引至28.25亿至28.75亿美元

美股速递
Jul 31

神经分泌生物科学公司(Neurocrine Biosciences, Inc)近日宣布,将其核心产品Ingrezza(Valbenazine)2026年的净销售额预期上调。新的预测区间设定在28.25亿美元至28.75亿美元之间。这一调整反映了公司对市场前景的乐观预期,以及该药物在治疗领域持续增长的动力。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10